No effect of Parkinson’s disease-polygenic load on striatal density of dopaminergic neuron in healthy subjects

[1]  Jong Hun Kim,et al.  Effect of polygenic load on striatal dopaminergic deterioration in Parkinson disease , 2019, Neurology.

[2]  Myung Jun Lee,et al.  Effect of Single-Nucleotide Polymorphisms on Decline of Dopamine Transporter Availability in Parkinson's Disease , 2018, Journal of clinical neurology.

[3]  D. Berg,et al.  Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[4]  Myung Jun Lee,et al.  Effects of rs591323 on serotonin transporter availability in healthy male subjects , 2018, Annals of Nuclear Medicine.

[5]  A. Singleton,et al.  Genetic risk factors in Parkinson’s disease , 2018, Cell and Tissue Research.

[6]  M. Nalls,et al.  A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci , 2017, Nature Genetics.

[7]  S. Aoki,et al.  Age-related effects and gender differences in Japanese healthy controls for [123I] FP-CIT SPECT , 2017, Annals of Nuclear Medicine.

[8]  M. Trost,et al.  Genetic Determinants of Parkinson's Disease: Can They Help to Stratify the Patients Based on the Underlying Molecular Defect? , 2017, Front. Aging Neurosci..

[9]  D. Hernandez,et al.  Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI) , 2016, Movement disorders : official journal of the Movement Disorder Society.

[10]  M. Vidailhet,et al.  Dopaminergic denervation severity depends on COMT Val158Met polymorphism in Parkinson's disease. , 2015, Parkinsonism & related disorders.

[11]  A. Waldman,et al.  The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1 , 2015, American Journal of Neuroradiology.

[12]  Chuong B. Do,et al.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.

[13]  Y. Okubo,et al.  Age-related decline in dopamine transporter in human brain using PET with a new radioligand [18F]FE-PE2I , 2014, Annals of Nuclear Medicine.

[14]  J. Foster,et al.  Mechanisms of dopamine transporter regulation in normal and disease states. , 2013, Trends in pharmacological sciences.

[15]  Chuong B. Do,et al.  Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database , 2012, PLoS genetics.

[16]  C. Duyckaerts,et al.  The second brain and Parkinson’s disease , 2009, The European journal of neuroscience.

[17]  Frank Baas,et al.  Striatal Dopamine Transporter Availability Associated with Polymorphisms in the Dopamine Transporter Gene SLC6A3 , 2008, Journal of Nuclear Medicine.

[18]  Donald Grosset,et al.  Role of dopamine transporter imaging in routine clinical practice , 2003, Movement disorders : official journal of the Movement Disorder Society.

[19]  Patrik Brundin,et al.  Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein , 2002, Nature Reviews Neuroscience.

[20]  J D Speelman,et al.  [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[21]  K. Laere,et al.  European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  Patrik Brundin,et al.  Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. , 2002, Nature reviews. Neuroscience.